Company intelligence / Profile preview

Cellesce

Cardiff, Wales, United Kingdom

Ownership: Private
Employees: ~4
Development stage: Other

Overview

Cellesce has developed and commercialized a patented technology to produce standardized patient-derived organoids (PDOs) at industrial scale, enabling consistent high-throughput drug screening in oncology. Their colorectal and breast cancer organoids are in commercial supply, with additional cancer types under development. The organoid technology was validated for fidelity to patient tumors, enabling more predictive preclinical drug discovery.

Therapeutic areas: Oncology
Modalities: Cell therapy
Industry: Non-Drug Biotech

Partnerships

Molecular Devices

Beyond the preview

Go deeper on Cellesce.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellesce.

Explore the full profile